ELAS
LIVE

Serial Number

88752241

Owner

Clinical Ink, Inc.

Attorney

Devon E. White

First Use Date

Aug 1, 2017

Filing Date

Jan 9, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ELAS Trademark

Serial Number: 88752241 • Registration: 6247177

ELAS is a trademark filed by Clinical Ink, Inc. on January 9, 2020. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Clinical Ink, Inc.

119 Brookstown Ave
Winston-Salem, NC 27101

Entity Type: 03

Trademark Details

Filing Date

January 9, 2020

Registration Date

January 12, 2021

First Use Anywhere

August 1, 2017

First Use in Commerce

August 1, 2017

Published for Opposition

May 5, 2020

Goods & Services

Providing clinical tools in the nature of a non-downloadable Software as a Service (SaaS) computer application that provides an integrated suite of Systemic Lupus Erythematosus (SLE) disease assessment questionnaires, physical assessment questionnaires, tender /swollen joint count questionnaires, Patient Global Assessment (PGA) questionnaires, and summary forms to simplify core assessments and eliminate the need for repetitive data entry in Lupus SLE studies; Providing clinical tools in the nature of a non-downloadable Software as a Service (SaaS) computer application that auto-populates the appropriate fields across an integrated suite of assessments and questionnaires to simplify core assessments and eliminate the need for repetitive data entry in Lupus SLE studies; Providing clinical tools in the nature of a non-downloadable Software as a Service (SaaS) computer application that combines multiple clinical assessments, defines the logic between them, and incorporates sophisticated data validations and workflow execution dynamics to simplify the complexity of administering these questionnaires to patients; Providing non-downloadable software as a service (SaaS) computer application featuring software tools for that allow for the remote review, management and analysis of clinical data, observational data, and structured workflows to facilitate the analysis of clinical process observations and to confirm and/ or clarify invalid or suspect data points; Conducting clinical trials for others in the field of lupus treatments and therapies; Medical and scientific research for others in the field of lupus treatments and therapies

Filing History

CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 15, 2026 APRE
TEAS SECTION 8 & 15 RECEIVED
Mar 20, 2026 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jan 12, 2026 REM1
REGISTERED-PRINCIPAL REGISTER
Jan 12, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Dec 11, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Dec 10, 2020 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Nov 16, 2020 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 10, 2020 AITU
USE AMENDMENT FILED
Oct 27, 2020 IUAF
TEAS STATEMENT OF USE RECEIVED
Oct 27, 2020 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 30, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 5, 2020 NPUB
PUBLISHED FOR OPPOSITION
May 5, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 15, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 28, 2020 CNSA
ASSIGNED TO EXAMINER
Mar 28, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 13, 2020 NWOS
NEW APPLICATION ENTERED
Jan 13, 2020 NWAP